TY  - CONF

T1  - Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (starms)

JO  - MULTIPLE SCLEROSIS JOURNAL

PY  - 2020/01/01

AU  - Sharrack B

AU  - Snowden J

AU  - Muraro P

ED  - 

VL  - 26

IS  - 3_SUPPL

SP  - 209

EP  - 210

Y2  - 2024/12/26

ER  -